I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-138
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.723B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |